Who owns Enochian Biosciences Inc?
- Ticker: RENB
- CUSIP Number: 29350e104
Tip: Access positions for across all investors
Analyze quarterly positions in Enochian Biosciences with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Enochian Biosciences stock
Who bought or sold Enochian Biosciences Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Vanguard Group | 3.9M | $10M | 904% | Mar 2024 |
|
| Geode Capital Management | 438k | $1.2M | 44% | Mar 2024 |
|
| Morgan Stanley | 375k | $995k | 181% | Mar 2024 |
|
| BlackRock | 314k | $833k | 11% | Mar 2024 |
|
| Goldman Sachs Group | 306k | $811k | 2279% | Mar 2024 |
|
| Millennium Management | 294k | $778k | 132% | Mar 2024 |
|
| Susquehanna International | 207k | $548k | 162% | Mar 2024 |
|
| Citigroup | 188k | $500k | 268% | Mar 2024 |
|
| Jane Street | 134k | $355k | 136% | Mar 2024 |
|
| Jpmorgan Chase & Co | 120k | $319k | 304% | Mar 2024 |
|
| Man Group | 108k | $286k | 100% | Mar 2024 |
|
| Commonwealth Equity Services | 102k | $269k | 100% | Mar 2024 |
|
| Northern Trust | 86k | $228k | 44% | Mar 2024 |
|
| Laurion Capital Management | 62k | $163k | 0% | Mar 2024 |
|
| ExodusPoint Capital Management | 59k | $156k | 100% | Mar 2024 |
|
| Qube Research & Technologies | 44k | $116k | 393% | Mar 2024 |
|
| Y-Intercept | 42k | $112k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 39k | $104k | 53% | Mar 2024 |
|
| Toroso Investments | 37k | $98k | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 36k | $96k | 0% | Mar 2024 |
|
| Marshall Wace | 34k | $91k | 100% | Mar 2024 |
|
| Brevan Howard Capital Management | 33k | $87k | 100% | Mar 2024 |
|
| Leucadia National Corporation | 32k | $85k | 94% | Mar 2024 |
|
| MSA Advisors | 25k | $79k | 100% | Dec 2023 |
|
| CTC Alternative Strategies | 21k | $57k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 20k | $53k | 100% | Mar 2024 |
|
| SG Americas Securities | 17k | $46k | 100% | Mar 2024 |
|
| William Blair $ Company | 16k | $43k | 0% | Mar 2024 |
|
| Hsbc Holdings | 15k | $49k | 100% | Dec 2023 |
|
| Squarepoint Ops | 15k | $39k | 100% | Mar 2024 |
|
| Victory Capital Management | 13k | $36k | 100% | Mar 2024 |
|
| Polymer Capital Management | 12k | $31k | 100% | Mar 2024 |
|
| Royal Bank of Canada | 5.4k | $14k | 100% | Mar 2024 |
|
| Lazard Asset Management | 3.9k | $0 | 100% | Dec 2023 |
|
| Point72 Asia | 1.9k | $4.9k | 100% | Mar 2024 |
|
| UBS Group | 1.8k | $4.9k | -77% | Mar 2024 |
|
| Bank of America Corporation | 1.8k | $4.7k | -96% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 1.2k | $3.1k | -3% | Mar 2024 |
|
| Wells Fargo & Company | 294.00 | $779.011800 | 2% | Mar 2024 |
|
Who sold out of Enochian Biosciences?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| 683 Capital Management | Dec 2023 | 74k | $234k |
| Citadel Advisors | Dec 2023 | 37k | $118k |
| Virtu Financial | Dec 2023 | 19k | $59k |
| Hrt Financial | Dec 2023 | 14k | $45k |
| Schonfeld Strategic Advisors | Dec 2023 | 13k | $43k |
| Bank of New York Mellon | Dec 2023 | 11k | $34k |